Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report) and Prothena (NASDAQ:PRTA – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.
Earnings and Valuation
This table compares Sangamo Therapeutics and Prothena”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sangamo Therapeutics | $39.55 million | 0.78 | -$122.93 million | ($0.38) | -0.19 |
| Prothena | $54.53 million | 9.21 | -$244.09 million | ($0.84) | -11.43 |
Volatility & Risk
Sangamo Therapeutics has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Prothena has a beta of -0.33, indicating that its share price is 133% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Sangamo Therapeutics and Prothena, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sangamo Therapeutics | 2 | 1 | 1 | 0 | 1.75 |
| Prothena | 1 | 1 | 5 | 1 | 2.75 |
Sangamo Therapeutics presently has a consensus target price of $5.50, suggesting a potential upside of 7,332.43%. Prothena has a consensus target price of $24.57, suggesting a potential upside of 156.03%. Given Sangamo Therapeutics’ higher possible upside, equities analysts clearly believe Sangamo Therapeutics is more favorable than Prothena.
Insider & Institutional Ownership
56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 97.1% of Prothena shares are held by institutional investors. 4.1% of Sangamo Therapeutics shares are held by insiders. Comparatively, 10.4% of Prothena shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Sangamo Therapeutics and Prothena’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sangamo Therapeutics | -310.81% | -2,662.06% | -132.12% |
| Prothena | -80.68% | -16.45% | -14.51% |
Summary
Prothena beats Sangamo Therapeutics on 10 of the 15 factors compared between the two stocks.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.
About Prothena
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer’s disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
